Press Releases

GlobeNewswire, Inc.

Delivers ~13% Net Sales Growth Company Updates 2026 Outlook; Raises Net Sales Guidance BEDMINSTER, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its first...

GlobeNewswire, Inc.

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at...

GlobeNewswire, Inc.

SINGAPORE, May 06, 2026 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), an integrated infrastructure provider of efficient altcoin mining and staking, today provided an update on the Company’s financial...

EIN Presswire

Lloyds Banking Group, Hack The Box, and Google Cloud Security host the first UK Financial Services Security Hackathon LONDON, UNITED KINGDOM, May 6, 2026 /⁨EINPresswire.com⁩/ -- Over the course of two days (April 27-28), banks, fintech companies,...

GlobeNewswire, Inc.

Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220...

GlobeNewswire, Inc.

First quarter Net Income of $72.9M and Adjusted Net Income of $9.0M Continued value driver execution and recent acquisitions drove first quarter Adjusted EBITDA of $41.2M First quarter Earnings Per Diluted Share of $0.44 and Adjusted Earnings Per...

GlobeNewswire, Inc.

-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, Minn., May 06, 2026 (GLOBE...

GlobeNewswire, Inc.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose-dependent pharmacokinetics; no...

GlobeNewswire, Inc.

Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted...

GlobeNewswire, Inc.

— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to...

GlobeNewswire, Inc.

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026 Initiation of Phase 1 study of...

GlobeNewswire, Inc.

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 – Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; enrollment completion expected in Q3...

GlobeNewswire, Inc.

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026...

GlobeNewswire, Inc.

First-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and...

GlobeNewswire, Inc.

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders,...

GlobeNewswire, Inc.

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in...

GlobeNewswire, Inc.

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Willis Lease Finance Corporation’s (NASDAQ: WLFC) board of directors as well as executive chairman Charles F. Willis,...

GlobeNewswire, Inc.

SHANGHAI, China, May 06, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that it will...

GlobeNewswire, Inc.

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026...

GlobeNewswire, Inc.

HONG KONG, May 06, 2026 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial...